Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 7/20 | 0.48 |
| ▸ | GCK | P35557 | 4/20 | 0.47 |
| ▸ | CSF1R | P07333 | 8/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 7/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16059181 | 0.91 | CSF1R (0.55) | TGFBR1GCKCSF1RPDGFRAPDGFRB | |
| SCHEMBL16037107 | 0.88 | TGFBR1 (0.45) | TGFBR1GCKCSF1RPDGFRAPDGFRB | |
| SCHEMBL16036583 | 0.88 | CSF1R (0.48) | TGFBR1GCKCSF1RPDGFRAPDGFRB | |
| SCHEMBL16036780 | 0.88 | CSF1R (0.48) | TGFBR1GCKCSF1RPDGFRAPDGFRB | |
| SCHEMBL16036678 | 0.87 | KDR (0.52) | — | |
| SCHEMBL16037333 | 0.84 | CSF1R (0.45) | TGFBR1CSF1RPDGFRAPDGFRBCYP2C9 | |
| SCHEMBL21426004 | 0.84 | TGFBR1 (0.49) | TGFBR1GCKCSF1RPDGFRAPDGFRB | |
| SCHEMBL30890876 | 0.83 | KDR (0.53) | CSF1RPDGFRAPDGFRB | |
| SCHEMBL21426332 | 0.83 | KDR (0.53) | CSF1RPDGFRAPDGFRB | |
| SCHEMBL16037120 | 0.83 | CSF1R (0.44) | TGFBR1CSF1RPDGFRAPDGFRBCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018214867-A9 | N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海和誉生物医药科技有限公司 | 2019-10-03 | — | — | WO | disclosed |
| US-9309224-B2 | N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS, LLC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20140275016-A1 | N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2014145029-A2 | N-ACYL-N'-(PYRIDIN-2-YL) UREAS AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275016-A1 | N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities | KIT, CSF1R, CSF3R | TGFBR1 1658/4885GCK 1551/4885CSF1R 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.